Primary ovarian insufficiency is a menopause-like condition affecting girls and young women, characterized by loss of menstrual periods, infertility, and hot flashes. A comprehensive plan provides recommendations for diagnosis and treatment, including hormone replacement therapy and counseling.
Researchers have discovered a gene expression signature associated with survival in advanced ovarian cancer. The study identified specific genes and pathways that correlate with overall survival, providing potential targets for therapies and personalized treatment strategies.
A meta-analysis of 10 studies confirms that risk-reducing salpingo-oophorectomy significantly reduces the risk of breast and ovarian cancers in women with BRCA mutations. The procedure is associated with a 51% relative reduction in breast cancer risk and an 79% relative reduction in ovarian cancer risk.
A new study published by the American Cancer Society found that obesity may contribute to the development of ovarian cancer through a hormonal mechanism. Women who were obese had an almost 80% higher risk of ovarian cancer compared to those of normal weight, particularly in women who had never used menopausal hormone therapy.
Researchers at the University of Texas M. D. Anderson Cancer Center discovered that a tumor-suppressing gene called ARHI acts as a switch for autophagy in ovarian cancer cells, allowing dormant cells to survive by avoiding starvation. Blocking this autophagic pathway could provide a novel strategy for eliminating dormant ovarian cancer...
Researchers found that obese and non-obese patients have the same overall survival rate for ovarian cancer if their chemotherapy doses are tailored to their individual body weight. The study, published in Gynecologic Oncology, challenges earlier research suggesting obesity reduces ovarian cancer survival rates.
Researchers at University of California, Berkeley discovered that blocking proteins coded by notorious gene MYC can stop ovarian cancer cell proliferation. By using RNA interference and small interfering RNA to silence L-Myc and N-Myc proteins, the scientists were able to shut down growth in non-amplified MYC tumors.
Researchers discovered that blocking proteins produced by the MYC oncogene can halt ovarian cancer cell proliferation. Using RNA interference, they silenced c-Myc and L-Myc proteins in lab cultures with amplified MYC, preventing cancer cell growth.
A recent Ontario study found that only 19% of women with invasive ovarian cancer were referred for genetic testing of BRCA1 and BRCA2 genes, highlighting a lack of awareness about the risks and benefits of genetic testing. This omission puts family members at risk as they are unaware of their potential cancer risk.
A phase III, international randomized clinical trial supports a new standard of treatment for women with advanced ovarian cancer, reducing complications and post-operative deaths. The study demonstrates that neoadjuvant chemotherapy followed by interval debulking surgery can be the preferred treatment for patients with very extensive d...
Research suggests ovarian cancer subtypes have distinct biomarker profiles, affecting patient outcomes and treatment strategies. The study analyzed 500 ovarian cancer samples to identify correlations between biomarkers and survival rates, highlighting the need for subtype-specific approaches.
Researchers at Johns Hopkins have discovered how ovarian tumors use fatty substances to suppress the body's immune response, leaving disease unchecked. The team found that fluid secretions from tumors can block activation of natural killer T cells, which are crucial for fighting cancer.
Research finds that PEA-15 protein forces ovarian cancer cells to eat themselves, leading to increased median survival time. High levels of PEA-15 are linked to improved patient outcomes and may offer a new dimension for targeting ERK in cancer therapy.
Research found skewed X inactivation in women with BRCA1 gene mutations, associated with a later onset of breast or ovarian cancer. The Impact of Cancer scale was also refined and validated, providing a tool to measure long-term psychosocial impact on cancer survivors.
Researchers have identified TEM1 as a specific genetic marker for the vascular cells associated with tumor growth in ovarian cancer. High levels of TEM1 were correlated with decreased survival rates, making it a potential screening tool for early detection.
A phase II trial of the investigational drug pazopanib has shown promising results in treating ovarian cancer. The study found that 31% of patients experienced a significant decrease in CA-125 levels, with a median duration of response of 113 days.
A new combination therapy of trabectedin and pegylated liposomal doxorubicin shows clinical benefit for women with relapsed ovarian cancer. The treatment offers an alternative to traditional platinum-based regimens, providing a fresh option for those whose cancer recurs after first-line treatment.
A phase III clinical trial led by UC Irvine's Dr. Bradley Monk found trabectedin to be effective in stopping ovarian cancer cell growth, with a median progression-free time of 9.2 months for those treated with the combination therapy. The treatment has hope for improved treatment of this deadly disease.
Researchers found overexpression of TG2 in ovarian cancer to be associated with increased tumor cell growth, adhesion, resistance to chemotherapy, and lower overall survival rates. Silencing TG2 using siRNA reversed cancer progression, suggesting the protein as a novel therapeutic approach for late-stage ovarian cancer.
A new ovarian stimulation technique allows women with cancer to collect eggs for freezing during the luteal phase, reducing wait time before treatment. The technique has shown promising results in triggering ovulation and collecting mature eggs within two weeks.
Researchers found that ovarian cancer has a distinct scent different from other cancers, which can be detected by trained dogs. Early-stage and low-grade ovarian cancers emit the same scent as advanced tumors.
A new study finds that combining symptom screening with a simple blood test can detect over 80% of women with early-stage ovarian cancer and nearly 95% with late-stage disease. This approach may lead to improved cure rates for those diagnosed at an earlier stage.
Researchers say combined PET/CT scanning can enable doctors to determine if ovarian cancer has spread without surgery, reducing unnecessary surgeries and complications. The technology showed promising results in accurately staging early-stage ovarian cancer patients.
A new study found that women with severe SLE who received a 6-month course of cyclophosphamide followed by mycophenolate mofetil treatment had preserved ovarian function and fertility. Disease activity was equally controlled in both groups, but patients treated with long-course CYC pulses had a higher risk of amenorrhea.
Researchers identified gene mutations in FIGLA as a cause of premature ovarian failure, which can lead to infertility and other health issues. The study found three types of mutations in the gene, highlighting its importance in ovary function.
Stored ovarian tissue from cancer patients may contain residual cancer cells that can re-infect the body if not checked. Research suggests that few fertility centers have the skills and technology to detect these cells, highlighting the need for improved testing methods.
Researchers at Yale University have discovered a new drug compound, NV-128, that can induce the death of ovarian cancer cells resistant to chemotherapy. The compound works by halting the activation of the mTOR protein pathway, which is associated with tumor growth and resistance to conventional therapies.
Researchers have identified and cloned ovarian cancer stem cells, which may be the source of recurrence and resistance to chemotherapy. These stem cells can replicate indefinitely and are highly resistant to conventional treatment.
Researchers have discovered that an enzyme called MMP-2 is necessary for ovarian cancer to attach itself to new sites, and that blocking its production can slow the spread of the disease. In a mouse study, early treatment with an MMP-2 inhibitor reduced tumor growth by 68% and nearly doubled survival time.
A nationwide study in the Netherlands found that women diagnosed with early-stage ovarian cancer treated at semispecialized or specialized hospitals survived longer than those treated at general hospitals. The estimated five-year survival improved with increasing specialization of the treatment facility, from 38% to 40.3%.
Researchers have developed a new test combining biomarkers HE4 and CA 125 to assess ovarian cancer risk. The test shows high sensitivity and specificity in predicting epithelial cancer, accurately stratifying patients as high or low risk.
Researchers found advanced-stage ovarian cancer patients with non-Ashkenazi Jewish BRCA mutations experience longer progression-free and overall survival rates compared to those without BRCA mutations. Additionally, a majority of women with ovarian cancer are unaware that BRCA testing is available, despite it potentially improving thei...
Researchers found that low-grade serous carcinoma of the ovary is less sensitive to chemotherapy than more common high-grade ovarian cancers. The overall response rate was only 4% in patients with recurrent disease, and no response was observed in women with platinum-resistant disease.
A University of Minnesota study has shown promising results for thalidomide as a treatment for recurrent ovarian cancer. Patients who received the combination of thalidomide and topotecan had a higher overall response rate and longer cancer-free period compared to those receiving topotecan alone.
A protein called interleukin-8 (IL-8) promotes tumor growth and angiogenesis in ovarian cancer. Researchers have identified IL-8 as a therapeutic target and tested short interfering RNA (siRNA) to silence its production, reducing tumor size by attacking its blood supply.
Researchers at Yale School of Medicine have developed a blood test that detects early stage ovarian cancer with 99% accuracy, building on previous work showing 95% effectiveness. The new platform uses six protein biomarkers instead of four, increasing specificity from 95 to 99.4%.
A team of researchers has identified a new mechanism that explains why some recurrent ovarian tumors become resistant to treatment with cisplatin and carboplatin. They found that secondary mutations on the BRCA2 gene restore DNA repair function, making cancer cells resistant to chemotherapy.
A collaborative study found that oral contraceptive use reduces ovarian cancer incidence by 8 per 1000 women before age 75. Long-term use significantly lowers mortality from the disease, preventing approximately two ovarian cancers and one death per 5000 woman-years of use.
A new study found no association between current or past smoking and ovarian cancer risk. However, an inverse trend of risk was observed with total caffeine and caffeinated coffee intake, particularly in women who had never used oral contraceptives or postmenopausal hormones.
A study published in The Lancet Oncology found that high-quality pre-operative ultrasound examinations can significantly decrease the number of unnecessary major surgical operations on women with suspected ovarian cancer. Experts' accuracy rates were 95%, while routine operators' accuracy was lower. Increasing ultrasound expertise is k...
Research published in the Journal of Clinical Oncology found that Ashkenazi Jewish women with BRCA1 or BRCA2 gene mutations have a significantly longer survival rate compared to those without these mutations. After up to nine years of follow-up, carriers were 28% less likely to die from ovarian cancer.
TGFBI, an extracellular matrix protein, induces microtubule stabilization and modulates sensitivity to paclitaxel in ovarian cancer cells. The study reveals that loss of TGFBI expression can induce resistance to taxane therapy.
Researchers have made significant progress in identifying new biomarkers for epithelial ovarian cancer, which can aid in early detection and improve treatment outcomes. The study highlights the potential of these biomarkers as therapeutic and imaging targets.
Researchers identified kisspeptin and GPR54 as independent prognostic biomarkers specific for ovarian clear cell carcinoma. These molecular markers are associated with a favourable prognosis and could potentially be used to monitor disease activity or as therapeutic agents in women with this subtype of ovarian cancer.
A new study found that experienced ultrasound examiners can accurately classify ovarian tumors using pattern recognition, outperforming blood test CA-125 levels. The method could improve diagnosis and treatment for women with ovarian cancer.
A Phase II trial of a new combination therapy for patients with platinum-resistant ovarian cancer showed a 33% overall response rate, twice as high as traditional chemotherapy regimens. The therapy combines flavopiridol and cisplatin and is promising for developing more effective treatments for this disease.
A low-fat diet was associated with a reduced risk of ovarian cancer in postmenopausal women, with the greatest reduction seen in those with high fat intake before the study. The findings suggest that a low-fat dietary pattern may be beneficial in reducing cancer incidence rates.
Researchers found that a low-fat dietary pattern reduced the risk of ovarian cancer by 40% in healthy postmenopausal women. The study followed 48,835 women for an average of 8.1 years and found no effect during the first four years due to the slow development of preventive benefits.
A new study of 24,479 Australian women found that those with high levels of physical activity were more likely to develop ovarian cancer, with a statistically significant dose-response effect. The study suggests exercise may not have the protective effects previously thought, but rather an increased risk, particularly at medium levels.
Pertuzumab prolongs survival time for women with Stage 3 ovarian cancer, a Phase II clinical trial found. The experimental drug added weeks to the standard survival period and was well-tolerated by the body.
A study found that the -765G>C COX2 polymorphism increases the risk of ovarian cancer by nearly two-fold in C allele carriers and nearly three-fold in women under 53. The mutation may enhance COX-2 gene expression, inhibiting apoptosis and promoting tumour proliferation.
A laboratory study found that cranberry compounds can sensitize human ovarian cancer cells resistant to platinum drugs, potentially improving chemotherapy effectiveness. The active compounds, called 'A-type' proanthocyanidins, appear to bind and block tumor promoter proteins in ovarian cancer cells.
A woman with damaged ovaries due to chemotherapy and radiotherapy received a successful transplant from her genetically non-identical sister, restoring her ovarian function. After six months, she started menstruating and had mature oocytes retrieved for fertilization.
A Penn State research team discovered that blocking km23, a traffic cop protein, disrupts the transport of a signaling component to the nucleus, leading to reduced gene expression and cell growth. The findings may lead to diagnostic tools and earlier treatments for ovarian cancer.
A novel mutation of the AKT1 gene has been found in breast, colorectal, and ovarian cancers, which may contribute to tumor cell proliferation. The mutation is believed to play a role in making cells resistant to certain therapies.
A new algorithm for personalized ovarian stimulation therapy has been developed, demonstrating improved pregnancy rates in women undergoing fertility treatment. The formula, based on four easily measured patient characteristics, was tested in a prospective clinical study involving 161 patients.
A study of 132 rare ovarian cancer survivors found that most retained menstrual function and reproductive ability after treatment. Despite reproductive concerns, survivors were more likely to be in meaningful, positive relationships than healthy counterparts.
Recent evidence shows ovarian cancer is preceded by symptoms like gastrointestinal or urinary issues in three to four months before diagnosis. Patient groups urge women to seek medical attention for new and persistent symptoms, while experts acknowledge the need for clinical judgement and more research funding.
Researchers at the University of Edinburgh have shown that hormone therapy can prolong the life of some ovarian cancer patients by up to three years. The study found that targeted use of an anti-oestrogen drug could slow the growth and spread of disease in highly sensitive cancers.
Researchers are conducting phase I trials comparing slow-freezing techniques to a rapid method of cryopreservation that transforms tissues into glass-like structures. The goal is to make human eggs, ovarian tissue, blood vessels, and whole organs available when needed.